USANA Q2 net sales $213M (-11% YoY), EPS $0.54 (-39%); cuts FY2024 guidance

USANA HEALTH SCIENCES INC

2024-Q2 EPS reported $1.40 revenue$440,669,000

Diluted EPS $0.54 vs. $0.89 in Q2 2023; net sales $213M down 11% YoY to $238M.
Active customers fell 4% YoY to 468,000; macro pressures and fewer promotions cited.
FY24 outlook: net sales $850-880M (prev $850-920M), EPS $2.40-2.55 (prev $2.40-3.00).
Operating margin revised to 8.0%-8.8%; effective tax rate raised to 43%-44%.
Cash $332M, no debt; no share repurchases in Q2; $62M authorization remaining.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.